If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
337
results.
Updated on
21/08/2026 [07:27:00]
Results 250 to 275 of 337
Absstract of: US20260184770A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Absstract of: JP2024019568A
To provide enrichment of an antigen-specific antibody for analytical and therapeutic use.SOLUTION: The present invention relates to a method for eliminating the interference described in the specification using particles (e.g., microparticles, nanoparticles; magnetic, non-magnetic) containing surfaces containing the capturing portions described in the specification, or enriching biomarkers, especially antibodies, prior to diagnostic testing, or isolating and using the antibodies for prophylactic or therapeutic purposes. The method described in the specification is a simple, efficient, and cost-effective method for the conditioning of biological samples for managing and mitigating a number of known sample-specific interferences that can lead to erroneous test results and increased risk to patient safety, such as heterophil antibodies in patients treated with monoclonal mouse antibodies or those receiving them for diagnostic purposes.SELECTED DRAWING: None
Absstract of: WO2026141950A1
The present application provides: a spectroscopic analysis substrate for diagnosing dementia, comprising a hydrophilized graphene layer; and a spectroscopic device comprising same. More specifically, the present application provides: a spectroscopic analysis substrate for diagnosing dementia, having improved accuracy due to increased binding force and selectivity for amyloid beta, the substrate comprising a hydrophilized graphene layer; and a spectroscopic device comprising the spectroscopic analysis substrate.
Absstract of: US20260186004A1
0000 It has been established that increased levels of lactylated of tau protein in the brain and CNS is associated with tauopathies and neurodegenerative diseases, and increased levels of lactylated lysine on tau protein has been established as a marked for AD. Compositions and methods for the detection and treatments of tauopathies have been developed. In some forms, the methods identify and quantify lactylated lysine on tau protein in a biological sample from a subject to diagnose a tauopathy, such as AD. In some forms, the methods identify a subject as having or at risk of having a tauopathy. In some forms, the methods include treating the tauopathy. Compositions to identify a tauopathy include lactylated tau binders, such as antibodies are also described. Compositions to treat or prevent a tauopathy, such as lactylated tau peptides having a defined lactyllysine, are also described.
Absstract of: WO2026143158A1
Disclosed herein methods and compositions for diagnosing, stratifying risk, and treating hypoxia-related brain disorders using NHIP genetic variants, DNA methylation signatures, and circulating NHIP peptide levels, as well as NHIP based peptide therapeutics for improving neurological and developmental outcomes.
Absstract of: WO2026142185A1
In a surface-enhanced Raman scattering-based method for testing drug reactivity of cerebrovascular cells, a SERS substrate is manufactured. A SERS substrate array including a plurality of the SERS substrates is manufactured. Cells are cultured on the SERS substrate array. A drug is administered to the cultured cells. A Raman signal is measured from the cells to which the drug is administered. An optimal drug is selected from among the administered drugs on the basis of the measured Raman signal.
Absstract of: WO2026139605A2
The invention relates to biomarkers for mitochondrial disease. Signalling lipids were identified as having good correlations with disease severity. Several of these biomarkers were found to correlate with treatment efficacy. Signalling lipids such as 15-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid showed a positive correlation with disease severity and showed a corresponding decrease after treatment of the disease.
Absstract of: WO2026139512A2
The present invention relates to methods of producing a conformationally constrained peptide in cellulo using a pnictogen-containing crosslinker. The present invention also relates to conformationally constrained peptides obtainable by said methods and a method for screening peptide libraries for transcription factor agonists that tests whether said conformationally constrained peptide inhibits association between two candidate binding partners. The present invention also relates to the use of a pnictogen-containing cross-linker in a method of producing a conformationally constrained peptide in cellulo. The present invention also relates to recombinant peptides comprising three thiol-/selenol-containing residues linked to a pnictogen-containing cross-linker. The present invention also relates to a kit for use in said methods.
Absstract of: JP2026110170A
【課題】本発明者らは、特に老化組織において炎症を抑制し得る素材をスクリーニングする技術の提供を主な目的とした。【解決手段】上記課題は、工程Ｂ：１５回以上継代された血管内皮細胞に被験物質を接触させる工程、並びに工程Ｃ：ＩＬ－６、ＩＬ－８、ＣＸＣＬ１、ＰＡＩ－１、ＭＭＰ－１、ＩＣＡＭ－１、ＶＣＡＭ－１、Ｅ－ｓｅｌｅｃｔｉｎ、及びＣＣＬ２からなる群より選択される少なくとも１種の炎症関連因子の、工程Ｂで被験物質を接触させた血管内皮細胞における発現量を評価する工程を含む方法により、解決され得る。【選択図】なし
Absstract of: US20260183364A1
The present disclosure relates to methods for treating or alleviating a fetal alcohol spectrum disorder (FASD) in a subject, the method comprising administering to the subject an effective amount of an apolipoprotein E (APOE)-modulating therapeutic, thereby treating or alleviating the FASD.
Absstract of: US20260184764A1
0000 The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.
Absstract of: AU2024388318A1
The present disclosure provides precision medicine or personalized therapy of using a Sigma-1 receptor agonist in treating neurological disease or disorder. The precision medicine or personalized therapy involves patient selection through differentially expressed genes or affected biological pathways related to the Sigma-1 receptor agonist therapy. Also provided are kits for practicing the methods.
Absstract of: WO2026137685A1
The present application relates to the technical field of immunochromatography, and in particular, to a test strip for detecting β-amyloid protein and the use thereof. In the present application, colored microspheres are conjugated to a β-amyloid monoclonal antibody via covalent bonds, and then the conjugate is coated onto a conjugate pad. Compared with colloidal gold, the colored microspheres exhibit greater stability and higher sensitivity. Additionally, the colored microspheres feature bright and diverse colors, uniform particle sizes, good monodispersity, and strong reproducibility of detection results. The test strip provided by the present application has the advantages of simplicity, rapidity and high timeliness, requires no additional reagents, instruments and professional personnel, and supports on-site operation. By means of simply applying a to-be-detected sample to a sample loading port of the test strip, a detection result can be interpreted within 15 min. The result interpretation is visual, intuitive, accurate and straightforward, with a low risk of human errors such as false positives and false negatives.
Absstract of: US20260184772A1
The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.
Absstract of: US20260185138A1
0000 A coupled tethered enzyme luminescence assay for measuring the amount of enzymatic activity of neural specific enolase in a liquid blood sample taken from a patient. The assay has a test well and a positive control well. The test well has a number of components including an inhibitor and a number of first tethered enzyme nanobots formed by tethering pyruvate kinase enzyme to silica nanoparticles, and a number of second enzyme nanobots formed by tethering luciferase molecules to silica nanoparticles for oriented immobilization of the tethered enzymes pyruvate and luciferase. The pyruvate kinase and luciferase enzymes have two differing types of affinity tags. One type of affinity tag facilitates extraction of enzymes from a liquid and another affinity tag for tethering to a silica nanoparticle. The positive control well includes the components of the test well and an added preset amount of enolase enzyme.
Absstract of: WO2026142751A1
Aspects of the disclosure include methods of treating an autoimmune disease, including reducing the need for chronic immunosuppression, and for effectuating immune reset and/or producing a naive B cell repertoire in a subject in need thereof, the methods comprising administering a therapeutically effective amount of anti-CD20 yδ T cells to the subject, wherein the anti-CD20 yδ T cells express a chimeric antigen receptor (CAR) comprising a binding domain that specifically binds to CD20.
Absstract of: WO2026137051A1
The present disclosure generally relates to a modified receptor and/or a modified ligand and uses thereof. The modified receptor and/or modified ligand can be used to establish molecular signalling between two biological components, rendering the modified receptor and/or modified ligand suitable in a broad array of applications.
Absstract of: WO2026142290A1
The present invention relates to a biomarker-specific binding probe and a use thereof. By introducing the probe into a nanopore, it is possible to accurately and rapidly detect the presence and abundance of a specific biomarker in a sample.
Absstract of: US20260185056A1
An in vitro method of producing a fused tissue culture with at least three different tissues including selecting a spatial shape for attaching the at least three different tissues to each other, placing the at least three different tissues into contact in the spatial shape, culturing the at least three different tissues under conditions that maintains tissue fusion of the at least three different tissues is disclosed. Further provided is a tissue culture comprising a planar or linear fusion of at least three different neural or neuronal tissues, uses thereof and means for its production.
Absstract of: US20260185993A1
0000 A functional peptide modified magnetic composite nanobead, and a method and an application thereof for detecting β-secretase (BACE1) and screening its inhibitors are provided. The chemical composition of the magnetic composite nanobead is: ferroferric oxide (Fe<3>O<4>) nanoclusters used as magnetic cores, the surface of the magnetic cores coated with a silica shell, the surface of the shell connected with an ethylene diamine tetraacetic acid (EDTA) modification layer, and Co<2+> or Ni<2+> ions chelated on the EDTA layer, and the Cy5 fluorescein labeled functional peptide coated on the surface of magnetic composite nanobead by the interaction between Co<2+> or Ni<2+> ions and hexahistidine-tag.
Absstract of: US20260187803A1
0000 Integrated platforms, systems, and associated processes for measuring lifespan, body size and shape, activity, pathology, pigmentation/color, and multiple in vivo molecular biomarkers using multiple cameras are described. The integrated platform includes a plate and trays supported on the plate. Each tray can hold animals. The integrated platform also includes an imaging module with a first camera and a second camera. The first camera can capture first images associated with movement of the animals and the second camera can capture second images and third images associated with biomarkers of the animals.
Absstract of: WO2018218193A1
The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.
Absstract of: KR20260101594A
본원은 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다. 더욱 상세하게, 본원은 아밀로이드 베타와의 결합력 및 선택성 증가로 정확도가 개선된 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다.
Absstract of: KR20260100566A
본 발명은 알파-시누클레인 단백질에 특이적으로 결합하는 DNA 앱타머 및 이의 용도에 관한 것으로, 구체적으로 본 발명은 서열번호 1 내지 12의 염기서열로 이루어진 군 중에서 선택되는 알파-시누클레인(α-synuclein) 단백질에 특이적으로 결합하는 DNA 앱타머(aptamer), 상기 앱타머를 유효성분으로 포함하는 알파-시누클레인 단백질 검출용 조성물, 검출용 키트, 검출용 칩 또는 마이크로어레이에 관한 것이며, 또한 본 발명은 본 발명의 DNA 앱타머를 이용한 알파-시누클레인 단백질의 검출방법, 퇴행성 뇌질환의 진단을 위한 정보 제공 방법, 퇴행성 뇌질환의 진단용 조성물 및 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물에 관한 것이다.
Nº publicación: CN122297477A 30/06/2026
Applicant:
山东大学
Absstract of: CN122297477A
0001 本发明涉及生物医药领域，公开了一种含有2,4‑噻唑环的化合物在抗衰老中的应用。含有2,4‑噻唑环的化合物为式X所示化合物或其药学上可接受的盐，其中式X化合物包括具有吡唑并嘧啶骨架的式I类化合物和具有吲哚骨架的式II类化合物。本发明人首次发现IL4I1是调控细胞衰老的关键分子，并阐明了式X化合物通过靶向IL4I1，解除IL4I1对EIF4B的泛素化降解，上调EIF4B‑PGAM5轴表达，从而维持线粒体稳态、延缓细胞及组织衰老的作用机制。实验结果表明，本发明所述含有2,4‑噻唑环的化合物可有效预防放化疗诱导的细胞衰老，减轻放疗诱导的小鼠整体衰老，改善运动功能，降低衰老相关分泌表型因子分泌，缓解器官纤维化。本发明为开发新型抗衰老药物提供了新的化学分子基础和作用靶点。
BOPI
Electronic site
